Omalizumab is a monoclonal antibody against IgE that is used as adjunctive therapy for severe allergic asthma.[1] A systematic review included nineteen studies and found that omalizumab significantly reduced asthma exacerbations by 38% and emergency room visits by 47% compared to control groups.[1] The treatment improved overall asthma control, patients' quality of life, and allowed a reduction in daily corticosteroid use.[1][2] The majority of included studies demonstrated low risk of bias and high methodological quality with moderate to high certainty evidence.[1] Omalizumab has a confirmed favorable safety profile, although serious allergic reactions, including anaphylaxis, may rarely occur.[3] Effectiveness is usually seen after at least 12–16 weeks of treatment.[4] This review confirms that omalizumab is an effective and safe treatment option for patients with severe allergic asthma that cannot be adequately controlled with inhaled corticosteroids.